Measured directly ex-vivo by a robust, accurate and cheap high-throughput technique, we found that low levels of BLR1 at baseline were indicative of more severe TB disease and increased the likelihood of an unfavourable treatment outcome at 2 months. Here, CXCR5 is linked to tuberculosis.